Application of MSCT Combined with Serum CA125 and CYFRA21-1 in the Diagnosis of Non-small Cell Lung Cancer

Ting WANG,Huiwen MA,Donglin WANG,Huiqing YU,Sixiong WANG,Enwen WANG
DOI: https://doi.org/10.3969/j.issn.2095-1264.2018.01.21
2018-01-01
Abstract:Objective To evaluate the diagnostic value of multi-slice spiral CT (MSCT) combined with serum sugar chain antigen-125(CA125) and cytokeratin 19 fragment 21-1(CYFRA21-1) in non-small cell lung cancer (NSCLC). Methods 100 NSCLC patients were selected as the NSCLC group, and 45 patients as the Lung benign lesion group, 45 healthy people as the Health group. All the research-ers underwent MSCT scan and the expression of serum CA125, CYFRA21-1, and the above results in the diagnosis and staging of non-small cell lung cancer were compared. Results In the NSCLC group, 36 cases of central type tumor and 48 cases of peripheral type tumor were detected by MSCT, and the positive rate was 84.00%. The levels of CA125 and CYFRA21-1 in serum of patients with NSCLC were significantly higher than that of patients with lung benign lesions and healthy subjects (P<0.05). The expression of CA125 in adenocarci-noma patients was significantly higher than that in squamous cell carcinoma patients, while the expression of CYFRA21-1 was significantly lower than that in squamous cell carcinoma (P<0.05). The sensitivity and specificity of MSCT, CA125 and CYFRA21-1 were 84.00% and 42.00%, 48.00% and 94.44%, 92.22% and 95.56%, respectively. The sensitivity of the three markers combined detection was 94.00%, which was significantly higher than that of single item (P<0.05). The specificity of each grop has no significant difference (P>0.05). Conclusion MSCT combined with CA125 and CYFRA21-1 can significantly improve the detection sensitivity of NSCLC, and provide a new method for clinical diagnosis.
What problem does this paper attempt to address?